{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:38:01Z","timestamp":1777574281025,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Archivel Farma s.l. (Badalona, Catalonia, Spain)"},{"name":"Spanish Government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.vaccine.2009.09.134","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T08:55:52Z","timestamp":1256288152000},"page":"1106-1116","source":"Crossref","is-referenced-by-count":112,"title":["Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI\u00ae"],"prefix":"10.1016","volume":"28","author":[{"given":"C.","family":"Vilaplana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Montan\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Barriocanal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.09.134_bib1","unstructured":"Organization WH. Global tuberculosis control: surveillance, planning, financing: WHO report 2008; 2008."},{"issue":"August (3)","key":"10.1016\/j.vaccine.2009.09.134_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.09.134_bib3","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2009.09.134_bib4","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Woldehanna","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"February (11)","key":"10.1016\/j.vaccine.2009.09.134_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.vaccine.2004.09.008","article-title":"Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis","volume":"23","author":"Cardona","year":"2005","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.09.134_bib6","first-page":"25","article-title":"Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection","volume":"42","author":"Cardona","year":"2006","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.vaccine.2009.09.134_bib7","doi-asserted-by":"crossref","unstructured":"Cardona P. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006;86(3\u20134):273\u201389.","DOI":"10.1016\/j.tube.2006.01.024"},{"key":"10.1016\/j.vaccine.2009.09.134_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/pds.2630010207","article-title":"Causality classification at pharmacovigilance centres in the European Community","volume":"1","author":"Meyboom","year":"1992","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2009.09.134_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt1977213247","article-title":"Toward the operational identification of adverse drug reactions","volume":"21","author":"Karch","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2009.09.134_bib10","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","article-title":"An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection","volume":"178","author":"Flynn","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.09.134_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1146\/annurev.immunol.22.012703.104635","article-title":"Immunity to tuberculosis","volume":"22","author":"North","year":"2004","journal-title":"Annu Rev Immunol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2009.09.134_bib12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2009.09.134_bib13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(06)70552-7","article-title":"Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design","volume":"6","author":"Ibanga","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.134_bib14","doi-asserted-by":"crossref","unstructured":"McShane H, Pathan A, Sander C, Goonetilleke N, Fletcher H, Hill A. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005;85(1\u20132):47\u201352.","DOI":"10.1016\/j.tube.2004.09.015"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2009.09.134_bib15","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"November (10)","key":"10.1016\/j.vaccine.2009.09.134_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Gu\u00e9rin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"Hoft","year":"2008","journal-title":"J Infect Dis"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.09.134_bib17","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1371\/journal.pmed.0050145","article-title":"Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations","volume":"5","author":"Hanekom","year":"2008","journal-title":"PLoS Med"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.09.134_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.molmed.2007.03.004","article-title":"The prognosis of latent tuberculosis: can disease be predicted?","volume":"13","author":"Andersen","year":"2007","journal-title":"Trends Mol Med"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2009.09.134_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1164\/rccm.200608-1099OC","article-title":"Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts","volume":"175","author":"Arend","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2009.09.134_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/CVI.00463-06","article-title":"Comparison of Mantoux and QuantiFERON TB Gold tests for diagnosis of latent tuberculosis infection in Army personnel","volume":"14","author":"Franken","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"November (10)","key":"10.1016\/j.vaccine.2009.09.134_bib21","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/497146","article-title":"Vdelta2+ gammadelta T cell function in Mycobacterium tuberculosis- and HIV-1-positive patients in the United States and Uganda: application of a whole-blood assay","volume":"192","author":"Rojas","year":"2005","journal-title":"J Infect Dis"},{"issue":"July (4)","key":"10.1016\/j.vaccine.2009.09.134_bib22","first-page":"901","article-title":"Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis","volume":"9","author":"Cheon","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2009.09.134_bib23","first-page":"586","article-title":"The effect of tuberculin skin testing on viral load and anti-mycobacterial immune responses in HIV-1-infected Ugandan adults","volume":"8","author":"Mawa","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"issue":"July (4)","key":"10.1016\/j.vaccine.2009.09.134_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.tube.2007.01.003","article-title":"Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy","volume":"87","author":"Di Liberto","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"issue":"July (4)","key":"10.1016\/j.vaccine.2009.09.134_bib25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tube.2007.01.002","article-title":"Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults","volume":"87","author":"Sahiratmadja","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"issue":"October (5386)","key":"10.1016\/j.vaccine.2009.09.134_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.282.5386.121","article-title":"An antimicrobial activity of cytolytic T cells mediated by granulysin","volume":"282","author":"Stenger","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2009.09.134_bib27","series-title":"Linear mixed models for longitudinal data","author":"Verbeke","year":"2000"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2009.09.134_bib28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-3083.2008.02103.x","article-title":"The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays","volume":"67","author":"Vilaplana","year":"2008","journal-title":"Scand J Immunol"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2009.09.134_bib29","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/CVI.00094-08","article-title":"Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis","volume":"15","author":"Guirado","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"April (5)","key":"10.1016\/j.vaccine.2009.09.134_bib30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.micinf.2005.12.004","article-title":"Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice","volume":"8","author":"Guirado","year":"2006","journal-title":"Microbes Infect"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2009.09.134_bib31","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/CDLI.2.6.726-732.1995","article-title":"Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients","volume":"2","author":"Hussain","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.09.134_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2249.1998.00452.x","article-title":"IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients","volume":"111","author":"Sousa","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"November (7)","key":"10.1016\/j.vaccine.2009.09.134_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1590\/S0074-02762008000700006","article-title":"Comparison of serological responses in two different populations with pulmonary tuberculosis","volume":"103","author":"Araujo","year":"2008","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2009.09.134_bib34","first-page":"308","article-title":"Immunoglobulin G, A, and M responses in serum and circulating immune complexes elicited by the 16-kilodalton antigen of Mycobacterium tuberculosis","volume":"9","author":"Raja","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2009.09.134_bib35","series-title":"Tuberculin treatment","author":"Riviere","year":"1913"},{"key":"10.1016\/j.vaccine.2009.09.134_bib36","series-title":"Sahli's tuberculin tratment","author":"Sahli","year":"1912"},{"issue":"November (16)","key":"10.1016\/j.vaccine.2009.09.134_bib37","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1097\/00002030-200311070-00010","article-title":"Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial","volume":"17","author":"Vuola","year":"2003","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.vaccine.2009.09.134_bib38","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2009.09.134_bib39","series-title":"Tuberculin in diagnosis and treatment","author":"Pottenger","year":"1913"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T06:29:00Z","timestamp":1590215340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09014947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0264410X09014947"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.134","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}